Effect of Hepatitis C Clearance on Insulin Resistance

• Status: Completed
• Trial end date: 2019-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Chronic hepatitis C infection has been linked to insulin resistance, which is the essential component of metabolic syndrome and type 2 diabetes mellitus. Resistin; an adipokine, has been demonstrated to stimulate the secretion of several inflammatory factors known to play a role in the induction of insulin resistance. we investigated the changes in insulin resistance after hepatitis C clearance in the era of direct antivirals.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Alexandria University
• Treatments: Ledipasvir; Ribavirin; Sofosbuvir

Criteria

Inclusion Criteria:

• Hepatitis C treatment-naïve;

• Non-diabetic patients.

Exclusion Criteria:

• Seropositivity for hepatitis B virus infection;

• Diabetes mellitus;

• Bbody mass index ≥ 30 Kg/M*2;

• History of alcohol consumption;

• Endocrinopathies that may affect the glycemic homeostasis;

• Other known causes of chronic liver disease; Hepatic decompensation [defined as history of gastrointestinal bleeding (melena and /or hematemesis), jaundice, coagulopathy, hepatic encephalopathy, and/or ascites]; bleeding diathesis;

• Connective tissue diseases;

• Autoimmune diseases;

• Cardiac, respiratory or renal disease.

• Patient receiving immuno-modulatory therapy or drugs that affect the blood glucose levels such as steroids or beta-blockers.